Guardant Health’s Shield Blood Test Gains EviCore Coverage, Expanding CRC Screening Access — Guardant Health, Inc.

Event summary

Guardant Health’s Shield blood test for colorectal cancer (CRC) screening will be covered by EviCore by Evernorth’s clinical guidelines starting January 1, 2027.
EviCore, the second-largest specialty benefits manager in the U.S., spans over 23 states, significantly expanding Shield’s reach.
Total covered lives for Shield now approximate 94 million, following prior coverage expansions from Carelon and UnitedHealth Group.
Shield is the first FDA-approved blood test for primary CRC screening in average-risk adults and is recommended by both the American Cancer Society and the National Comprehensive Cancer Network.

The big picture

Guardant Health’s Shield blood test is gaining traction as a non-invasive alternative to traditional colorectal cancer screening methods. The coverage by EviCore by Evernorth, combined with prior expansions from Carelon and UnitedHealth Group, positions Shield to capture a significant share of the CRC screening market. This aligns with broader industry trends toward more accessible and less invasive cancer detection methods, particularly as CRC rates rise among younger adults.

What we're watching

Commercial Adoption: How Guardant Health will leverage this coverage expansion to further penetrate the CRC screening market and compete with traditional screening methods.
Regulatory Dynamics: Whether the inclusion of Shield in major clinical guidelines will accelerate its adoption by other insurers and healthcare providers.
Market Penetration: The pace at which Guardant Health can convert covered lives into actual test usage, given the high screening adherence rates reported.